Filing Analysis
Prelude Therapeutics announced a $85.5 million securities offering consisting of common stock and pre-funded warrants. The capital raise, led by RA Capital Management, is intended to fund clinical development and extend the company's cash runway into the second quarter of 2028.
Red Flags
- Significant dilution of existing shareholders through the issuance of over 20 million new shares/equivalents.
Key Facts
- Agreement to sell 18,018,014 shares of common stock at $4.44 per share.
- Agreement to sell 2,252,252 pre-funded warrants at $4.4399 per warrant with a $0.0001 exercise price.
- Estimated net proceeds of approximately $85.5 million after fees and expenses.
- Offering led by RA Capital Management with participation from Soleus Capital.
- Company expects existing cash plus offering proceeds to fund operations into Q2 2028.
- Underwriters include Goldman Sachs & Co. LLC and Evercore Group L.L.C.
Prelude Therapeutics announced positive preclinical data for its lead development candidate PRT13722, a first-in-class KAT6A degrader, at the AACR Annual Meeting 2026. The company remains on track to file an Investigational New Drug (IND) application in mid-2026.
Key Facts
- PRT13722 is a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader.
- Preclinical data showed durable complete tumor regressions in HR+/HER2- breast cancer xenograft models as a monotherapy.
- The candidate demonstrated synergy with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.
- PRT13722 showed an improved preclinical hematological safety profile compared to prifetrastat.
- IND filing is targeted for mid-2026 with Phase 1 initiation anticipated in H2 2026.
Prelude Therapeutics Incorporated has appointed Dr. Charles Q. Morris as its new Chief Medical Officer, effective April 20, 2026. Dr. Morris brings significant industry experience from previous CMO roles at Lava Therapeutics, Celyad Oncology, and Radius Health.
Key Facts
- Dr. Charles Q. Morris appointed as Chief Medical Officer effective April 20, 2026.
- Initial annual base salary set at $535,000 with a discretionary bonus target of 40%.
- Granted an option to purchase 450,000 shares of common stock, vesting over four years.
- Dr. Morris previously served as CMO at Lava Therapeutics N.V. until its acquisition by XOMA Royalty in October 2025.
- Severance terms include 9 months of base salary and healthcare, or 12 months plus 100% equity acceleration if terminated following a change in control.
Prelude Therapeutics filed a prospectus supplement to sell up to $25.0 million of common stock through an 'at-the-market' (ATM) offering facility with Jefferies LLC. This offering is part of a previously established $75.0 million sales agreement and utilizes the company's existing shelf registration statement.
Red Flags
- Potential shareholder dilution resulting from the issuance of up to $25.0 million in new common stock.
Key Facts
- The company filed a prospectus supplement on March 12, 2026, to sell up to $25.0 million of common stock.
- Jefferies LLC is acting as the sales agent for the offering.
- The offering utilizes an existing Shelf Registration Statement on Form S-3 (File No. 333-279829) declared effective on June 10, 2024.
- The underlying Open Market Sale Agreement with Jefferies was originally entered into on March 15, 2023, for up to $75.0 million.
Prelude Therapeutics announced its full-year 2025 financial results and released an updated investor presentation on March 10, 2026.
Key Facts
- Reported financial results for the fiscal year ended December 31, 2025
- Furnished a press release as Exhibit 99.1 on March 10, 2026
- Released updated investor presentation materials as Exhibit 99.2
- The report was signed by Bryant Lim, Chief Financial Officer and Chief Legal Officer